Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-Identified Data From South Africa

Key Points

• To evaluate the risk of major adverse cardiovascular events (MACE) associated with dolutegravir versus efavirenz in PLHIV in South Africa.
• Emulated target trials using routine, de-identified data.
• Population included PLHIV in South Africa.
• Comparison of outcomes between dolutegravir and efavirenz-based antiretroviral therapy.
• No increased risk of major adverse cardiovascular events with dolutegravir compared to efavirenz.
• Findings suggest dolutegravir is a safe treatment option in this population.